BRPI0519755A2 - composiÇÕes ou combinaÇÕes nutrientes terapÊuticas e uso dos mesmos - Google Patents

composiÇÕes ou combinaÇÕes nutrientes terapÊuticas e uso dos mesmos

Info

Publication number
BRPI0519755A2
BRPI0519755A2 BRPI0519755-4A BRPI0519755A BRPI0519755A2 BR PI0519755 A2 BRPI0519755 A2 BR PI0519755A2 BR PI0519755 A BRPI0519755 A BR PI0519755A BR PI0519755 A2 BRPI0519755 A2 BR PI0519755A2
Authority
BR
Brazil
Prior art keywords
combination
combinations
nutrient compositions
prepared
composition
Prior art date
Application number
BRPI0519755-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Daren K Heyland
Original Assignee
Critical Care Connections Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Connections Inc filed Critical Critical Care Connections Inc
Publication of BRPI0519755A2 publication Critical patent/BRPI0519755A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0519755-4A 2004-12-21 2005-12-21 composiÇÕes ou combinaÇÕes nutrientes terapÊuticas e uso dos mesmos BRPI0519755A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63765704P 2004-12-21 2004-12-21
PCT/CA2005/001944 WO2006066404A1 (en) 2004-12-21 2005-12-21 Therapeutic nutrient compositions or combinations and methods of their use

Publications (1)

Publication Number Publication Date
BRPI0519755A2 true BRPI0519755A2 (pt) 2009-03-10

Family

ID=36601322

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519755-4A BRPI0519755A2 (pt) 2004-12-21 2005-12-21 composiÇÕes ou combinaÇÕes nutrientes terapÊuticas e uso dos mesmos

Country Status (9)

Country Link
US (1) US20080131525A1 (https=)
EP (1) EP1841445A4 (https=)
JP (2) JP2008524123A (https=)
CN (1) CN101084003A (https=)
AU (1) AU2005318832B2 (https=)
BR (1) BRPI0519755A2 (https=)
CA (1) CA2588911C (https=)
WO (1) WO2006066404A1 (https=)
ZA (1) ZA200705824B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004762B2 (en) 2013-05-08 2018-06-26 Gambro Lundia Ab Dialysis formulation
EP3490971A4 (en) * 2016-08-01 2020-02-26 Filament Biosolutions Inc. METHODS OF TREATING AND PREVENTING SIDE EFFECTS OF CANCER TREATMENT
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
CN120420344B (zh) * 2025-07-08 2025-09-05 中国人民解放军总医院第三医学中心 一种眼用药物组合物及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
DE4304172A1 (de) * 1993-02-12 1994-08-25 Bayer Ag Fungizide Wirkstoffkombinationen
US5561111A (en) * 1994-12-23 1996-10-01 The University Of Virginia Patent Foundation Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy
US6022867A (en) * 1996-11-27 2000-02-08 Showa Denko Kabushiki Kaisha Method of administering vitamin E to animals and compositions containing tocopheryl phosphates and salts thereof for animals
DE69739663D1 (de) * 1996-12-31 2009-12-31 Antioxidant Pharmaceuticals Co Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
US5849335A (en) * 1997-06-02 1998-12-15 Nestec S.A. Composition and method for providing glutamine
WO1999021565A1 (en) * 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
US6649746B1 (en) * 1999-05-07 2003-11-18 University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes
US6805880B1 (en) * 1999-08-20 2004-10-19 Ferrosan A/S Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
US6890896B1 (en) * 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
AU5625001A (en) * 2000-04-18 2001-10-30 Societe Des Produits Nestle S.A. Nutritional modules
US6479068B1 (en) * 2000-06-30 2002-11-12 Baxter International Inc. Therapeutic nutrient regimen for alleviating mucositis, stomatitis and cachexia in oncology patients
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
US6552076B2 (en) * 2000-12-15 2003-04-22 Mitokor Compounds for altering mitochondrial function and cellular responses
PL363426A1 (en) * 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US6660293B2 (en) * 2001-06-29 2003-12-09 Everett Laboratories, Inc. Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
DE10151764A1 (de) * 2001-10-19 2003-05-08 Basf Ag Kombination von Liponsäure und Glutamin in Lebens- und Arzneimitteln
JP2003192586A (ja) * 2001-12-27 2003-07-09 Ss Pharmaceut Co Ltd IL−1β抑制剤
DE10221403A1 (de) * 2002-05-14 2003-12-04 Kyberg Pharma Vertriebs Gmbh & Diätetische und pharmazeutische Zusammensetzungen, ihre Herstellung und ihre Verwendung
US6645514B1 (en) * 2002-12-19 2003-11-11 Access Business Group International, Llc Increasing skin cell renewal with water-soluble Vitamin E

Also Published As

Publication number Publication date
EP1841445A1 (en) 2007-10-10
JP2008524123A (ja) 2008-07-10
JP2012107023A (ja) 2012-06-07
AU2005318832B2 (en) 2011-07-07
WO2006066404A1 (en) 2006-06-29
CA2588911A1 (en) 2006-06-29
AU2005318832A1 (en) 2006-06-29
EP1841445A4 (en) 2010-06-02
CA2588911C (en) 2013-04-23
US20080131525A1 (en) 2008-06-05
CN101084003A (zh) 2007-12-05
ZA200705824B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
BR112014010275A2 (pt) formulações para tratamento de diabetes
CR9348A (es) Composicion farmaceutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cancer
BR112015022585A2 (pt) composto, uso de um composto, e, conjugado droga-anticorpo
ECSP088866A (es) Uso de inhibidores de dpp iv
EA200900626A1 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
BRPI0905369B8 (pt) composição farmacêutica, uso da composição farmacêutica e kit compartimentado
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
BRPI0706676B8 (pt) uso de uma solução aquosa com potencial de oxirredução
BRPI0612669B8 (pt) composição imunogênica, vacina, composição, e composição liofilizada
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
BRPI0915064B8 (pt) derivados de quinoxalinadiona, seus usos, e medicamentos
BR112013025517A2 (pt) uso de 2,3-diidroimidazo[1,2-c]quinazolinas substituídas
BR112014008400A2 (pt) derivados de 2-carboxamida cicloamino ureia em combinação com os inibidores de hsp90 para o tratamento de doenças proliferativas
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
BR112013026573A2 (pt) fórmula de lactente para uso na prevenção de doenças cardiovasculares
MX2009011900A (es) Curacion de herida diabetica.
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
WO2007056264A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
BRPI0519755A2 (pt) composiÇÕes ou combinaÇÕes nutrientes terapÊuticas e uso dos mesmos
BRPI0700133A (pt) composição farmacêutica compreendendo tramadol e cetoprofeno em combinação
RU2012100621A (ru) Композиция для инъекций, содержащая гидроксихлорохин, для местного применения при лечении геморроя
BRPI0815280A2 (pt) medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
BR112015008964A2 (pt) composições injetáveis estáveis contendo diclofenaco e tiocolquicosídeo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: FRESENIUS KABI DEUTSCHLAND GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]